At the same time, studies showed that the activity of DNase I is reduced in AAV patients which decreases NET degradation and makes PR3 and MPO available for ANCA [98]. This evidence concerns the gene MPO and anti-neutrophil cytoplasmic antibody-associated vasculitis.